DFTX Company Profile and Key Details

DFTX has shown sold momentum, gaining 20.89% over the past week and 22.93% over the past quarter, though year-to-date performance is up 25.32%. Short-term trend indicators are bearishly aligned (SMA20 0.97%, SMA50 11.63%, SMA200 53.73%). The stock’s 14-day RSI is 55.31 (neutral), while the ATR of 1.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.54% below its high and over 267.87% above its low. Average 10-day trading volume of 1.48 million shares is below the 3-month average of 1.70 million, indicating normal recent market interest.

Definium Therapeutics, Inc. (NASDAQ:DFTX) closed at $22.15 USD, gaining $0.22 (1.00%) from the previous close of $21.93. The stock is currently within 5% of its 52-week high $12.88 and $22.72. With a market capitalization of about $2.21 billion, Definium Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.56). Key stats such as the average daily volume over the past year has been around 2.53 million shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Definium Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Barrow, the company employs approximately 74 people and listed since November 15, 2016. Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

Definium Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 12.11%. Wall Street analysts project EPS growth of -0.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $25.00. The high target offers 219.2% upside. The low target suggests 14.0% downside. The mean target is $42.00. This offers 91.52% upside. Definium Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 50.0%. The prior quarter beat by 31.58%. Over the last six quarters, Apple has recorded several small beats. These include 24.24% in March 06, 2025.

Definium Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.89. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Definium Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.45%, with price expected at $24.88 by April 28, 2026, within a range of $24.23 to $25.55 3-Month Outlook: Projected rise of 21.66%, reaching $26.68 by July 13, 2026, with a range of $26.57 to $26.78. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 14, 2027, within a range of $0.00 to $0.00.

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares are up 25.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Definium Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.67. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $42.00, suggesting 91.52% upside. Our AI forecast model points to short-term strength (13.45% over two weeks), a medium-term rise (21.66% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Definium Therapeutics, Inc. trades at a P/E ratio of -10.67, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.9 trading at moderately above to book value. The P/FCF stands at -16.77, also below market averages.